Brain metastases are a very common manifestation of cancer that have historically been
approached as a single disease entity given the uniform association with poor clinical …

Brain metastases occur commonly in patients with advanced solid malignancies. Yet, less is
known about brain metastases than cancer-related entities of similar incidence. Advances in …

PURPOSE Conventional wisdom has rendered patients with brain metastases ineligible for
clinical trials for fear that poor survival could mask the benefit of otherwise promising …

Importance Lung cancer is the leading cause of cancer-related mortality in the United States
and worldwide. As systemic therapies improve, patients with lung cancer live longer and …

Purpose To update the Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for a
markedly heterogeneous patient population, patients with melanoma and brain metastases …

Purpose Patients with lung cancer and brain metastases represent a markedly
heterogeneous population. Accurate prognosis is essential to optimally individualize care. In …

Introduction Management of central nervous system (CNS) metastases in patients with driver-
mutated NSCLC has traditionally incorporated both tyrosine kinase inhibitors (TKIs) and …

The improved survival outcomes of patients with non-small-cell lung cancer (NSCLC),
largely owing to the improved control of systemic disease provided by immune-checkpoint …

Brain metastasis (BM) is the most common event in patients with lung cancer. Despite
multimodal treatments and advances in systemic therapies, development of BM remains one …

Brain metastases occur in almost one-third of adult patients with solid tumor malignancies
and lead to considerable patient morbidity and mortality. The rising incidence of brain …